A guide to finding out your breast cancer risk, and whether you should be tested for BRCA mutations. I like my boobs. They’re great. They look fine in a T-shirt, it feels good when they're touched, ...

The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

Genetics is always changing. It seems as if every day there is a new article about a new study, and trying to navigate all of this information can be quite confusing. This past month, a new study was ...

Should screening for BRCA1/2 mutations be expanded to all women diagnosed with breast cancer? This is the recommendation put forth in recent guidelines from the American Society of Clinical Oncology ...

Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital. Background: A BRCA1 gene mutation is well-known risk factor for breast ...

Lynparza significantly improves iDFS, DDFS, and OS in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients. The trial's six-year analysis shows consistent benefits across all ...

When we hear about mutations like the BRCA gene, it's usually associated with women and breast cancer screening. But researchers say not only do men get breast cancer, but the gene also shows risks ...

Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45 Myriad Genetics, Inc. (NASDAQ: ...